Paris – COVID-19 vaccines have brought billions of dollars to the coffers of pharmaceutical companies.
Germany’s BioNTech SE, maker with partner Pfizer Inc. of a pioneering messenger RNA (mRNA) shot, raised its vaccine revenue forecast for 2021 in its latest earnings report Monday.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.